CG Oncology (CGON) Share-based Compensation (2023 - 2026)

CG Oncology has reported Share-based Compensation for 4 years, with the latest figure at $6.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 25.68% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $28.0 million (up 86.21% YoY), and the FY2025 full-year result was $26.7 million, up 133.96% from the prior year.
• Share-based Compensation for Q1 2026 stood at $6.5 million, down from $7.2 million in the prior quarter.
• The five-year high for Share-based Compensation was $7.3 million in Q3 2025, with the low at $177000.0 in Q2 2023.
• Historically, Share-based Compensation has averaged $3.5 million across 4 years, with a median of $2.6 million in 2024.
• Annual changes were most pronounced in 2024 — Share-based Compensation surged 1168.93% — and 2026, when it rose 25.68%.
• CG Oncology's Share-based Compensation stood at $778000.0 in 2023, then surged by 541.39% to $5.0 million in 2024, then soared by 44.03% to $7.2 million in 2025, then slipped by 9.92% to $6.5 million in 2026.
• The last three Share-based Compensation figures came in at $6.5 million (Q1 2026), $7.2 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.